about
Mucosal immunisation: adjuvants and delivery systems.Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease ModelsTowards the development of a broadly protective group a streptococcal vaccine based on the Lipid-Core Peptide system.Self-adjuvanting lipopeptide vaccines.Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products.Modern subunit vaccines: development, components, and research opportunities.Endosome Escape Strategies for Improving the Efficacy of Oligonucleotide Delivery Systems.Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor.Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors.Peptide based DNA nanocarriers incorporating a cell-penetrating peptide derived from neurturin protein and poly-L-lysine dendrons.Progress in vaccine development.Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.Vaccine delivery: synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate.Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine.An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system.Nanosized, peptide-based multicomponent DNA delivery systems: optimization of endosome escape activity.Investigation toward multi-epitope vaccine candidates using native chemical ligation.Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.Bombesin/oligoarginine fusion peptides for gastrin releasing peptide receptor (GRPR) targeted gene delivery.Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.Glucagon-like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities Beyond Type 2 Diabetes.Design and evaluation of a stearylated multicomponent peptide-siRNA nanocomplex for efficient cellular siRNA delivery.Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines.Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluationMethod for the synthesis of highly pure vaccines using the lipid core peptide systemMethod for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligationStructure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidatesToward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccinesVaccine delivery utilizing liposaccharidesSite-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccinesGlucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their EfficiencyPeptide-based targeted polymeric nanoparticles for siRNA deliveryA Self-Adjuvanting Vaccine Platform: Optimization of Site-Specific Sortase A Mediated Conjugation of Toll-Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein AntigensDispersibility of phospholipids and their optimization for the efficient production of liposomes using supercritical fluid technologySupercritical fluid assembly of albendazole liposomes targeting gastrin-releasing peptide receptor overexpressing tumorsNeutralisation of adeno-associated virus transduction by human vitreous humour
P50
Q36320761-D39E994C-774E-4589-BF16-BD98E10D3050Q37027300-A35AA509-279B-44D0-83E4-CC5FF8B78442Q37066039-40F7A758-757E-40C9-BC0D-3C1F47429AC0Q37090084-5DC9E924-9ACF-41A8-9DBE-FF807A7AC428Q37661001-0DA69350-6A91-41A7-98DE-2461343F68FFQ38073752-AF7F6A3A-1CD6-45F5-99FA-049B17562F42Q38572839-0B436B1B-CAAC-4176-82B1-BA70408FDFBCQ38737699-D186AC7A-1192-4702-9073-5BB9C9EE47DCQ39176475-C3698E4C-1BD1-4095-AF13-A2B85C3213BEQ40143465-E4E85822-F272-4F49-9413-BB1BA6EA3D1FQ40378322-E6F114B5-4548-4190-A984-EFBE15F08FE0Q41060768-31731340-6AFC-44A4-B1BA-67D47C84BE18Q41510529-2E46EEE2-9ED1-49B7-AE02-12990236FA67Q41588446-34653304-6712-416E-8987-4EFD0BB13C74Q43541747-CF899F17-79E1-4239-B6FC-00D21AA017E7Q44545446-5E5409B4-3C39-4929-8F81-371B20DA96A8Q45224329-C88EF537-D234-4A22-ABEB-D7FD72252EABQ45884120-D7733C0B-A54F-45CC-89D4-0FE97D0BCD59Q46268154-F0E68890-000D-4362-A85E-742C922D16ECQ46751101-C0A7BCC5-F176-4D5D-9200-08ACAAA3D9EDQ47561610-8708F8E0-A241-45F9-B0BE-8E13FB4C68DFQ47824275-794E1E27-32BE-4AC9-B282-809D47C9BFEBQ50048017-1C75ED54-31AB-4222-980D-5B5A108E022AQ50210562-61B20D51-2F15-48AE-9A0E-9BDACB6C05A4Q55333118-FAEEEFCB-FA28-4A06-8A1D-190084C2BB1FQ79223337-619C5A50-44E5-4530-8FBA-995CCA8B1D85Q79387808-D5B6C4A8-18A1-4ECF-8AC1-6EA12A0C8342Q80161681-E95041A2-BD1A-40CD-B8D2-368981FBC86DQ80179308-777215AA-4B5D-4F22-B473-AF4CF46709C1Q80809913-A22BAFBB-E4AF-44B2-AE57-945590211BA5Q83740855-A93D26CD-33C0-4E49-B234-6D7FB501CCFDQ87637932-A989FD10-023C-4309-B584-D7A1EAB8EC21Q91726341-FCF2E173-22F9-45D4-8F58-88D5A85D302FQ91800493-F04CEEA7-5CAC-492E-AE15-4F06D59CC917Q92686430-0FADC59F-7894-4C69-951C-AE9202A14B37Q92799494-E91B2D03-5EC6-47D4-819F-FA4CB548B6F8Q96133062-69715876-262A-4524-8424-5AAFD507C343Q96431757-5EB91C8A-56A6-4D07-9586-6DA5B03168F5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter M. Moyle
@ast
Peter M. Moyle
@en
Peter M. Moyle
@es
Peter M. Moyle
@nl
Peter M. Moyle
@sl
type
label
Peter M. Moyle
@ast
Peter M. Moyle
@en
Peter M. Moyle
@es
Peter M. Moyle
@nl
Peter M. Moyle
@sl
altLabel
Peter Michael Moyle
@en
prefLabel
Peter M. Moyle
@ast
Peter M. Moyle
@en
Peter M. Moyle
@es
Peter M. Moyle
@nl
Peter M. Moyle
@sl
P1053
H-1536-2011
P106
P1153
8280977800
P2013
P21
P2798
P31
P3829
P496
0000-0002-9247-681X